Intraarticular corticosteroid injection into rheumatoid arthritis knees improves extensor muscles strength

1990 ◽  
Vol 9 (6) ◽  
pp. 265-270 ◽  
Author(s):  
P. Geborek ◽  
B. M�nsson ◽  
F. A. Wollheim ◽  
U. Moritz
2011 ◽  
Vol 38 (6) ◽  
pp. 1009-1011 ◽  
Author(s):  
CHRISTIAN H. ROUX ◽  
VERONIQUE BREUIL ◽  
LAURE VALERIO ◽  
NICOLAS AMORETTI ◽  
OLIVIER BROCQ ◽  
...  

Objective.To compare etanercept (anti-tumor necrosis factor-α) with intraarticular (IA) corticosteroid injections to treat rheumatoid arthritis (RA).Methods.Patients with RA who had persistent monoarthritis received etanercept or IA corticosteroid injections. Efficacy was compared at Weeks 4 and 24.Results.Thirty-four patients were included (8 dropped out). Mean age was 58.8 years. No difference between groups was found at Weeks 4 or 24, but both groups showed significant improvement at Weeks 4 and 24 compared to baseline.Conclusion.Etanercept and IA steroid injections resulted in significant improvement at Week 4 that persisted to Week 24. There was no significant difference in outcome between the groups.


2013 ◽  
Vol 72 (7) ◽  
pp. 1267-1269 ◽  
Author(s):  
Yasuo Nagafuchi ◽  
Shuji Sumitomo ◽  
Yoko Soroida ◽  
Takeyuki Kanzaki ◽  
Yukiko Iwasaki ◽  
...  

Author(s):  
Johanna Margaretha Kroese ◽  
Sigvard Kopp ◽  
Frank Lobbezoo ◽  
Per Alstergren

Abstract Objectives To evaluate the effect of corticosteroid injections in the painful temporomandibular joint (TMJ) of patients with rheumatoid arthritis (RA) in relation to systemic inflammatory activity. Method Examination of 35 patients (median age 54 years; 89% female) included maximum mouth opening capacity, degree of anterior open bite (AOB), TMJ pain intensity at rest, and crepitus. Serum levels of rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serotonin, and plasma levels of interleukine-1β (IL-1β) were determined. Out of the 70 examined joints, 53 joints received a corticosteroid (methylprednisolone) injection after the clinical examination at baseline (T0). The examination was repeated for all patients at T1 (median 3.1 weeks after T0), and for 21 patients at T2 (median 6.3 weeks after T1), of whom 20 patients received a second injection at T1. Results Maximum mouth opening capacity significantly increased, and TMJ pain intensity significantly decreased between T0 and T1, but these improvements were no longer present at T2. No differences were found in AOB between the time points. Of the joints that received an injection at T0, 19 joints had pretreatment crepitus, which resolved in eight joints at T1. No correlations were found between the change in mouth opening capacity or TMJ pain intensity and ESR, CRP, serotonin, or IL-1β. Conclusions Methylprednisolone injections in the TMJ alleviate pain and improve mouth opening capacity for approximately 3 weeks, allowing patients to perform jaw exercises during this timeframe of temporary relief. It thus seems useful for the short-term management of TMJ involvement in RA. Key Points• In rheumatoid arthritis, corticosteroid injection in the temporomandibular joint alleviates pain and improves function.• The clinical improvement achieved with methylprednisolone injections lasts for approximately 3 weeks.• Corticosteroid injections could be used to facilitate and support additional noninvasive, conservative treatment options.


2001 ◽  
Vol 28 (1) ◽  
pp. 89-93 ◽  
Author(s):  
J. R. Garcia-Lozano ◽  
M. F. Gonzalez-Escribano ◽  
A. Valenzuela ◽  
A. Garcia ◽  
A. Nunez-Roldan

Sign in / Sign up

Export Citation Format

Share Document